One hundred seventy seven sera from 112 patients with acute leukemia, malignant lymphoma, other hematopoietic disorders or cancer were assayed for lymphocytotoxic antibody (LCT antibody) and 100 sera from 58 patients were assayed for antiplatelet antibody using mixed passive hemoagglutinative technique (platelet mixed passive hemoagglutinative antibody=P-MPHA antibody) recently developped by Shibata, et al.
Thirty three out of 112 patients (29.5%) had LCT antibody and 22 out of 58 patients (37.9%) had P-MPHA antibody.
About 90% of these antibodies was found to be generated after repeated transfusions from random donors. Twenty eight out of 74 patients (37.8%) who received blood transfusions from random donors developped LCT antibody, and 20 out of 44 patients (45.5%) developped P-MPHA antibody. The incidence of these antibodies was elevated with frequency of blood transfusions.
However, 40% of patients who had more than 100 units of blood transfusions failed to develop these antibody.
Sera from 57 patients were examined for both LCT and P-MPHA antibodies, and nine of them were proved to have both antibodies. Nine patients had only LCT antibody and 13 patients had only P-MPHA antibody.
Twenty six patients had no antibody.
